← SynDRA
LEVOSALBUTAMOL
SynDRA canonical compound SYN0003073 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | ADRB2 |
|---|
| Mechanism of action | Adrenergic receptor agonist |
|---|
| Indication | bronchospasm |
|---|
| Disease area | pulmonary |
|---|
All known targets
Mechanisms of action (all sources)
- Adrenergic receptor agonist
- ADRB2 AGONIST
- Beta-2 adrenergic receptor agonist
- ADRB2 ANTAGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- CYP1A2
- CYP2C19
- CYP2C9
- CYP2D6
- CYP3A4
- HDAC6
- HIF1A
- NFKB1
- SLCO1B1
- SLCO1B3
- TSHR
Drug classes
- Adrenergic beta2-Agonists
- beta2-Adrenergic Agonist
Cross-references
Synonyms
- LEVALBUTEROL HYDROCHLORIDE
- XOPENEX
- XOPENEX HFA
- Xopenex
- xopenex
- levalbuterol HCl
- (-)-Salbutamol
- (R)-Salbutamol
- levalbuterol
- levalbuterol hydrochloride
- levalbuterol tartrate
- Albuterol (r)-form
- Levalbuterol
- R-salbutamol
- ASF-1096
- (R)-salbutamol
- R-Salbutamol
- R-Albuterol
- (r)-(-)-salbutamol
- UNII-EDN2NBH5SS
- EDN2NBH5SS
- CHEBI:8746
- Levosalbutamol (INN)
- Levosalbutamol [INN]
- (R)-albuterol
- R-salbutamol sulphate
- Albuterol (r)-
- (-)-Albuterol
- levosalbutamolum
- Levalbuterol Inhalation
- RefChem:56698
- Hydrochloride, Levalbuterol
- Hydrochloride, Levosalbutamol
- DTXCID40110455
- levalbuterol inhalation 0.31mg/3mL
- levalbuterol inhalation 0.63mg/3mL
- levalbuterol inhalation 1.25mg/3mL
- (-)-Albuterol sulfate (1
Reported adverse events
- Anxiety
- Back pain
- Cough
- Dizziness
- Dyspepsia
- Hypertonia
- Migraine
- Nervousness
- Pain
- Rhinitis
- Sinusitis
- Tachycardia
Look up LEVOSALBUTAMOL in the interactive SynDRA portal →